Search Results - Vincent Ribrag

Refine Results
  1. 1

    Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation? by Selma Addou, Clémentine Sarkozy, Julien Lazarovici, Stéphane Champiat, Aspasia Stamatoullas, Fabrice Jardin, Vincent Ribrag, Aurélien Marabelle, Jean-Marie Michot

    Published in Human Vaccines & Immunotherapeutics (2021-10-01)
    Get full text
    Article


  2. 2

    Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma by Lars P. Jordheim, Vincent Ribrag, Hervé Ghesquieres, Sophie Pallardy, Richard Delarue, Hervé Tilly, Corinne Haioun, Fabrice Jardin, Delphine Demangel, Gilles A. Salles, Charles Dumontet

    Published in Haematologica (2015-05-01)
    Get full text
    Article


  3. 3

    Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic... by Jean-Marie Michot, Zsofia Balogh, Jennifer R. Brown, Vincent Ribrag, Antoine Hollebecque, Rastislav Bahleda, Cyril Quivoron, Samy Ammari, Jean-Yves Scoazec, Karim A. Benhadji, Christophe Massard

    Published in Therapeutic Advances in Drug Safety (2025-07-01)
    Get full text
    Article


  4. 4

    PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUB... by Jake Shortt, Brian Poligone, Vincent Ribrag, Pier Luigi Zinzani, Dima El-Sharkawi, Jan Walewski, Anca Prica, Laksmi Wilson, Sonia Souza, Harold Keer, Jason Taylor, Enrica Marchi

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  5. 5

    474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, tri... by Rachel Sanborn, Stephen Ansell, Vincent Ribrag, Diwakar Davar, Ecaterina Dumbrava, Elena Garralda, Carmen Belli, Clementine Sarkozy, Honey Kumar Oberoi, Amitkumar Mehta, Jasmine Zain, Alex Herrera, Andres Forero-Torres

    Published in Journal for ImmunoTherapy of Cancer (2021-11-01)
    Article


  6. 6

    Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review by Aythami deArmas‐Castellano, Diego Infante‐Ventura, Tasmania delPino‐Sedeño, Yadira González Hernández, Raul Quiros, Beatriz León‐Salas, Vincent Ribrag, María M. Trujillo‐Martín, ERN EuroBlood Working Group

    Published in Cancer Medicine (2025-02-01)
    Get full text
    Article


  7. 7

    Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study by Raphaël Busson, Marleen van der Kaaij, Nicolas Mounier, Berthe M. P. Aleman, Catherine Thiéblemont, Aspasia Stamatoullas, Vincent Ribrag, Hervé Tilly, Corinne Haioun, René-Olivier Casasnovas, Hanneke C. Kluin-Nelemans, Michel Henry-Amar

    Published in Health and Quality of Life Outcomes (2019-07-01)
    Get full text
    Article


  8. 8

    Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study by Vincent Ribrag, Won Seog Kim, Reda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Arpad Illes, Bernard Lemieux, Martin J. S. Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser

    Published in Haematologica (2017-05-01)
    Get full text
    Article


  9. 9

    Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma by Cyril Quivoron, Anthony Tarabay, Jean-Marie Michot, Arnaud Pagès, Hélène Lecourt, Anne Aupérin, Alina Danu, Julien Lazarovici, Julien Rossignol, David Ghez, Peggy Dartigues, Véronique Vergé, Christophe Massard, Valérie Camara-Clayette, Vincent Ribrag, Clémentine Sarkozy

    Published in Haematologica (2022-03-01)
    Get full text
    Article


  10. 10

    P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY by Won-Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalya Mikhaylova, Ana Marin-Niebla, Dejan Radeski, Vincent Ribrag, Eva Domingo Domènech, Ahmed Sawas, Karenza Alexis, Michael Emig, Linta Garcia, Andre Overesch, Kerstin Pietzko, Steven Horwitz

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  11. 11

    A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis by Claire Harrison, Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino, Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou, Davide Germano, Jacqueline Ewan, Vincent Ribrag

    Published in HemaSphere (2022-08-01)
    Get full text
    Article


  12. 12

    ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study by Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul G. Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Luděk Pour

    Published in Haematologica (2023-08-01)
    Get full text
    Article


  13. 13

    Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma by Vincent Ribrag, Dolores Caballero, Christophe Fermé, Emanuele Zucca, Reyes Arranz, Javier Briones, Christian Gisselbrecht, Gilles Salles, Alessandro M. Gianni, Henry Gomez, Carmen Kahatt, Claudia Corrado, Sergio Szyldergemajn, Sonia Extremera, Bernardo de Miguel, Martin Cullell-Young, Franco Cavalli

    Published in Haematologica (2013-03-01)
    Get full text
    Article


  14. 14

    P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS by Enrique Maria Ocio San Miguel, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, Maria-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Ludek Pour

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  15. 15

    Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma by María Victoria Mateos, Felipe Prosper, Jesús Martin Sánchez, Enrique M. Ocio, Albert Oriol, Cristina Motlló, Jean‐Marie Michot, Isidro Jarque, Rebeca Iglesias, María Solé, Sara Martínez, Carmen Kahatt, Salvador Fudio, Gema Corral, Ali Zeaiter, Lola Montilla, Vincent Ribrag

    Published in Cancer Medicine (2023-02-01)
    Get full text
    Article


  16. 16

    S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY by Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Vannucchi, Rami S. Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne Palmer, Kelly Mccaul, Vincent Ribrag, Srdan Verstovsek, Francesco Passamonti

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  17. 17

    Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study by Morgane Cheminant, Coralie Derrieux, Aurore Touzart, Stéphanie Schmit, Adrien Grenier, Amélie Trinquand, Marie-Hélène Delfau-Larue, Ludovic Lhermitte, Catherine Thieblemont, Vincent Ribrag, Stéphane Cheze, Laurence Sanhes, Fabrice Jardin, François Lefrère, Richard Delarue, Eva Hoster, Martin Dreyling, Vahid Asnafi, Olivier Hermine, Elizabeth Macintyre

    Published in Haematologica (2016-03-01)
    Get full text
    Article


  18. 18

    RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies by Camille Bigenwald, Yacine Haddad, Cassandra Thelemaque, Agathe Carrier, Roxanne Birebent, Pierre Ly, Caroline Flament, Imran Lahmar, Eric de Sousa, Markus Maeurer, Makoto Miyara, Tarek Assi, Cristina Castilla-Llorente, Christophe Willekens, Céline Fayemi, Julien Lazarovici, Aurélien Marabelle, Lisa Derosa, Vincent Ribrag, Laurence Zitvogel

    Published in OncoImmunology (2023-12-01)
    Get full text
    Article


  19. 19

    EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma by Mats Jerkeman, Igor Aurer, Elias Campo, Chan Y. Cheah, Jonathan Clark, Jeanette Doorduijn, Toby A. Eyre, Martin Fehr, Eva Giné, Maria Gomes da Silva, Pavel Klener, Marco Ladetto, Vincent Ribrag, Ofer Shpilberg, Jan Walewski, Martin Dreyling, the EHA Guidelines Committee and the European MCL Network

    Published in HemaSphere (2025-10-01)
    Get full text
    Article


  20. 20

    P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY. by Clementine Sarkozy, Catherine Thieblemont, Lucie Oberic, Anne Moreau, Kamal Bouabdallah, Gandhi Laurent Damaj, Thomas Gastinne, Vincent Ribrag, Rene Olivier Casasnovas, Corinne Haioun, Roch Houot, Fabrice Jardin, Eric Van Den Neste, Morgane Cheminant, Franck Morschhauser, Mary Callanan, Herve Ghesquieres, Remy Gressin, Olivier Hermine, Steven Le Gouill

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


Search Tools: